US 20210293819A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0293819 A1**

Davis (43) **Pub. Date: Sep. 23, 2021**

(54) **METHOD FOR IDENTIFYING CANCER-SPECIFIC ANTIBODIES UTILIZING IMMUNE CHECKPOINT INHIBITION**

(71) Applicant: **Elliot Davis**, Longwood, FL (US)

(72) Inventor: **Elliot Davis**, Longwood, FL (US)

(21) Appl. No.: **16/822,307**

(22) Filed: **Mar. 18, 2020**

Publication Classification

(51) **Int. Cl.**

G01N 33/574	(2006.01)
C07K 16/30	(2006.01)
A61K 35/17	(2006.01)

(52) **U.S. Cl.**

CPC ***G01N 33/574*** (2013.01); ***A61K 35/17*** (2013.01); ***C07K 16/30*** (2013.01)

(57) **ABSTRACT**

Inhibition of immune checkpoints in cancer patients may induce the patients B cells to generate antibodies against their cancer cells. The present disclosure provides methods for isolating, identifying, and characterizing these cancer-specific antibodies, and/or their antibodies/antigen binding sites. In particular, the presently disclosed methods relate to isolating, identifying, and characterizing cancer-specific antibodies from cancer patients in conjunction with an acute treatment of checkpoint inhibitor/s, and methods of generating cancer-specific medications thereof.